|
Updates in pediatric cardiomyopathy treatment development
FDA Expands Camzyos Approval to Adolescents with Obstructive HCM
The FDA has approved Bristol Myers Squibb’s Camzyos® (mavacamten) for adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) who weigh at least 30 kg (66 lbs). The milestone follows years of research and clinical collaboration, including an adolescent clinical trial led in part by CCF Medical Advisors Dr. Joseph W. Rossano and Dr. Charles E. Canter. Children in the CCF community also participated. Read the announcement →
Tenaya Therapeutics: FDA Grants RMAT Designation to Investigational Gene Therapy
Tenaya's investigational gene therapy TN-401 received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Read the announcement →
Cytokinetics: New Data for Aficamten in Non-Obstructive HCM
Cytokinetics reported additional ACACIA-HCM study results for aficamten in non-obstructive HCM. Read the announcement →
Rocket Pharmaceuticals: FDA Alignment on Danon Disease Gene Therapy Study
Rocket Pharmaceuticals announced FDA alignment on the path to complete its Phase 2 study of RP-A501, an investigational gene therapy for Danon disease, a rare condition that can cause cardiomyopathy. Read the announcement →
|